Concepedia

Shui He

SH

Statistics

Publications

17

Citations

2.3K

H-Index

15

Active since

2005

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Medical College of Wisconsin

Ospedale di Circolo e Fondazione Macchi

Incyte (United States)

Case Western Reserve University

Shui He is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, immunology, and radiation oncology.

Top concepts

Publications per year

2005–2023

17

Publications

17

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer et al. · New England Journal of Medicine · 2015 · 851 citations

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio et al. · The Lancet Oncology · 2021 · 397 citations

, , +6

Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients

Kyle J. Gunnerson, Melissa Saul, Shui He et al. · Critical Care · 2006 · 392 citations · Full text

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi et al. · Cancer · 2013 · 174 citations · Full text

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Brad S. Kahl, Mehdi Hamadani, John Radford et al. · Clinical Cancer Research · 2019 · 102 citations

1–5 of 17